Latanoprost Free Base | CAS# 130209-82-4 (free base) | OCULAR HYPERTENSION

Latanoprost Free Base
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414930

CAS#: 130209-82-4 (free base)

Description: Latanoprost Free Base is a prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Chemical Structure

Latanoprost Free Base

CAS# 130209-82-4 (free base)

Instruction

Theoretical Analysis

MedKoo Cat#: 414930
Name: Latanoprost Free Base
CAS#: 130209-82-4 (free base)
Chemical Formula: C26H40O5
Exact Mass: 432.29
Molecular Weight: 432.600
Elemental Analysis: C, 72.19; H, 9.32; O, 18.49

Price and Availability

Size	Price	Availability
50mg	USD 750	2 Weeks
100mg	USD 1250	2 Weeks
200mg	USD 2050	2 Weeks
500mg	USD 2950	2 Weeks
1g	USD 3950	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 130209-82-4 (free base); 41639-83-2 (acid); 130209-82-4 (ethanol solution)

Synonym: Latanoprost Free Base; PhXA41; PhXA-41; PhXA 41; XA41; XA-41; XA 41

IUPAC/Chemical Name: 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester, (1R-(1-alpha(Z),2-beta(R*),3-alpha,5-alpha))-

InChi Key: GGXICVAJURFBLW-ISHZQQPLSA-N

InChi Code: InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21?,22-,23-,24+,25-/m1/s1

SMILES Code: O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](CCC(O)CCC2=CC=CC=C2)[C@H](O)C[C@@H]1O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 432.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Asrani S, Robin AL, Serle JB, Lewis RA, Usner DW, Kopczynski CC, Heah T; MERCURY-1 Study Group. Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial. Am J Ophthalmol. 2019 Nov;207:248-257. doi: 10.1016/j.ajo.2019.06.016. Epub 2019 Jun 21. PMID: 31229466.

2: Mehran NA, Sinha S, Razeghinejad R. New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. Eye (Lond). 2020 Jan;34(1):72-88. doi: 10.1038/s41433-019-0671-0. Epub 2019 Nov 6. PMID: 31695162; PMCID: PMC7002400.

3: Kurysheva NI. Dolgosrochnoe primenenie latanoprosta v lechenii glaukomy [Long-term use of latanoprost in the treatment of glaucoma]. Vestn Oftalmol. 2020;136(2):125-132. Russian. doi: 10.17116/oftalma2020136021125. PMID: 32366080.

4: Grierson I, Jonsson M, Cracknell K. Latanoprost and pigmentation. Jpn J Ophthalmol. 2004 Nov-Dec;48(6):602-12. doi: 10.1007/s10384-004-0110-y. PMID: 15592791.

5: Aihara M, Lu F, Kawata H, Iwata A, Odani-Kawabata N, Shams NK. Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study. Am J Ophthalmol. 2020 Dec;220:53-63. doi: 10.1016/j.ajo.2020.06.003. Epub 2020 Jun 10. Erratum in: Am J Ophthalmol. 2021 Aug 27;: PMID: 32533949.

6: Sinha S, Lee D, Kolomeyer NN, Myers JS, Razeghinejad R. Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension. Expert Opin Pharmacother. 2020 Jan;21(1):39-45. doi: 10.1080/14656566.2019.1685499. Epub 2019 Oct 30. PMID: 31663782.

7: Muñoz-Negrete FJ, Arnalich-Montiel F, Lara-Medina FJ, Rebolleda G. Latanoprost-induced Skin Hypopigmentation. J Glaucoma. 2018 Mar;27(3):e72. doi: 10.1097/IJG.0000000000000878. PMID: 29334483.

8: El-Ashmawy AA, El-Maadawy IH, El-Maghraby GM. Efficacy of topical latanoprost versus minoxidil and betamethasone valerate on the treatment of alopecia areata. J Dermatolog Treat. 2018 Feb;29(1):55-64. doi: 10.1080/09546634.2017.1330527. Epub 2017 Jun 15. PMID: 28521549.

9: Oliveira ACS, Oliveira PM, Cunha-Filho M, Gratieri T, Gelfuso GM. Latanoprost Loaded in Polymeric Nanocapsules for Effective Topical Treatment of Alopecia. AAPS PharmSciTech. 2020 Nov 5;21(8):305. doi: 10.1208/s12249-020-01863-1. PMID: 33151434.

10: Horne RR, Rich JT, Bradley MW, Pitt WG. Latanoprost uptake and release from commercial contact lenses. J Biomater Sci Polym Ed. 2020 Jan;31(1):1-19. doi: 10.1080/09205063.2019.1669126. Epub 2019 Sep 27. PMID: 31526302.

Your view history

Latanoprost Free Base featured